Positive initial overall survival data were, however, attenuated and may not be clinically meaningful in a longer-term analysis 

Negative results are reported in SKYSCRAPER-03, while induction immunochemotherapy is investigated as a potential novel approach for unresectable stage II NSCLC  

The combination, incorporating the novel antibody–drug conjugate, may transform first-line treatment in the setting, but crucial issues need to be addressed

Phase III data show significant survival improvements with the TROP2-directed antibody–drug conjugate after progression on EGFR tyrosine kinase inhibitors

Positive results are reported from the FZOCUS-1 and ICON8B studies

As it emerges from some studies presented across different cancers, toxicity remains a major challenge

In the CAPItello281 trial, survival results with capivasertib plus abiraterone are promising, but questions remain on the accurate determination of PTEN loss in patients 

Tarlatamab as first-line therapy and ceralasertib plus durvalumab as maintenance therapy have demonstrated potential efficacy and manageable tolerability

Results from the NorthStar trial highlight the potential for integrating local therapy with targeted agents to extend disease control in this setting